Clinical Applications of Psychedelic Drugs 

He Benny Chang

R2 Talk


Clinical Applications of Psychedelic Drugs

What is the difference between a hallucinogen and a psychedelic drug?

Hallucinogens are a broad category of drugs that cause ‘hallucinations’. Psychedelics are a type of hallucinogen that work via 5-HT2A receptor agonism.

Briefly recount the history of psychedelic drugs.

Psychedelics have been used for thousands of years, but have had a surge during the past century. It became a schedule I controlled substance in 1970.

How safe are psychedelic drugs?

Among illicit/recreational substances, psychedelic drugs relatively lower levels of harm to both the individual and society at large. It is not associated with decreased mental health.

How might psychedelic drugs provide clinical benefit?

It could potentially improve psychologic wellness in certain patient populations, eg. Patients with terminal illness. The effects might also be long-lasting, with clinical effects seen well beyond the timeframe of acute usage.

How do psychedelics work?

Serotonin (5-HT2A ) agonist. It has decreases the activity of the default mode network in the brain, which is elevated in certain disorders.

Page Break


  • Beaussant, Y., Sanders, J., Sager, Z., Tulsky, J. A., Braun, I. M., Blinderman, C. D., Bossis, A. P., & Byock, I. (2020). Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians’ and Investigators’ Perspectives. Journal of Palliative Medicine, 23(10), 1323–1334.

  • Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8.

  • Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411.

  • El-Seedi, H R et al. 2005. “Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas”, Journal of Ethnopharmacology 101 (1-3): 238-242.

  • Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632.

  • Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280–288.

  • Kast, E. (1966). LSD and the dying patient. Chic Med Sch Q 26, 80-87.

  • Kast, E.C., and Collins, V.J. (1964). Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg 43, 285-291.

  • Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and Mental Health: A Population Study. PLoS ONE, 8(8), e63972.

  • Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047–1053.

Previous Eye Emergencies

Connect with Us!

University of Iowa © 2024. All Rights Reserved